Form 4: SpringWorks Therapeutics Chief Accounting Officer Disposes of Shares and Options Following Merger with Merck KGaA

SpringWorks Therapeutics' Chief Accounting Officer, Michael Nofi, disposed of all his common stock, restricted stock units, performance share units, and stock options as a result of the company's merger with Merck KGaA, Darmstadt, Germany, effective July 1, 2025, with shares converted to $47.00 cash per share.

Summary

• Michael Nofi, Chief Accounting Officer of SpringWorks Therapeutics, Inc. (SWTX), reported the disposition of all his beneficial ownership in the company.
• The disposition occurred on July 1, 2025, as a direct result of the merger of SpringWorks Therapeutics with EMD Holdings Merger Sub, Inc., a wholly-owned subsidiary of Merck KGaA, Darmstadt, Germany.
• Under the merger agreement, each outstanding share of SpringWorks Therapeutics common stock was cancelled and converted into the right to receive $47.00 in cash, without interest and subject to any required tax withholding.
• Nofi disposed of 30,623 shares of common stock, which included 19,682 shares underlying restricted stock units (RSUs).
• He also disposed of 8,661 performance share units (PSUs), which were converted into cash based on the merger consideration and performance achievement.
• Additionally, Nofi disposed of 203,546 stock options with exercise prices ranging from $25.45 to $43.00. Vested options were converted to cash based on the difference between the merger consideration and the exercise price.
• Unvested options and RSUs were converted into Parent Cash-Based Option Awards and Parent Cash-Based RSU Awards, respectively, which will generally vest according to their original terms, with a special provision for 50% vesting on the nine-month anniversary of the merger closing, subject to continued employment.
• Any outstanding options with an exercise price greater than $47.00 were cancelled for no consideration or payment.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders who received a cash premium for their shares and for employees whose unvested equity was converted into cash-based awards with some accelerated vesting. However, it's neutral to slightly negative for holders of out-of-the-money options that were cancelled without consideration. Overall, the transaction provides a clear, positive outcome for most equity holders.

Positives

• Shareholders received a cash payment of $47.00 per share, providing liquidity and a defined return.
• The merger provides a clear exit strategy for existing equity holders.
• Unvested equity awards (RSUs, PSUs, options) were converted into cash-based awards, preserving value for employees, with accelerated vesting for 50% of unvested tranches after nine months, subject to continued employment.

Negatives

• Options with an exercise price greater than $47.00 were cancelled for no consideration, resulting in a loss of potential value for holders of those specific options.
• The company is no longer an independent publicly traded entity, removing future growth potential for existing shareholders.
• The disposition of all securities means the reporting person no longer has direct equity upside in SpringWorks Therapeutics.

Risks

• Risk of forfeiture of unvested cash-based awards if employment with Parent (Merck KGaA) is not continued through vesting dates.
• Options with an exercise price above the merger consideration of $47.00 were cancelled without payment, representing a loss for holders of those specific options.

Future Outlook

The document primarily reports a past transaction (the merger becoming effective) and its immediate financial consequences for the reporting person's equity holdings. The future outlook for the company as an independent entity is that it will operate as a wholly-owned subsidiary of Merck KGaA. For employees with unvested awards, the future outlook includes continued employment with Parent to realize the full value of their cash-based awards, with a partial acceleration of vesting after nine months.

Industry Context

This merger signifies consolidation within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies like Merck KGaA acquire smaller, innovative biotech firms like SpringWorks Therapeutics to expand their pipeline and therapeutic areas. Such acquisitions are common strategies for growth and intellectual property acquisition in the industry.

Comparison to Industry Standards

• The acquisition of a biotech company by a large pharmaceutical firm is a common industry trend, reflecting the value placed on innovative drug pipelines and R&D capabilities.
• The conversion of equity awards (RSUs, PSUs, stock options) into cash or cash-based awards with continued vesting provisions is a standard practice in M&A transactions to retain key talent post-acquisition.
• The cancellation of out-of-the-money options (exercise price above merger consideration) is also a standard practice in such cash-out mergers.

Stakeholder Impact

• Shareholders: Received $47.00 cash per share, providing a definitive return and liquidity.
• Employees (including Michael Nofi): Unvested equity awards converted to cash-based awards, with continued vesting tied to employment, offering retention incentives and a path to realizing value. Those with out-of-the-money options lost potential value.
• Company (SpringWorks Therapeutics): Now a wholly-owned subsidiary of Merck KGaA, losing its independent public status.
• Merck KGaA (Parent): Successfully acquired SpringWorks Therapeutics, expanding its portfolio.

Next Steps

• Continued employment of Michael Nofi with Parent (Merck KGaA) to ensure vesting of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards.
• Vesting of 50% of then-unvested tranches of Parent Cash-Based RSU Awards and Parent Cash-Based Option Awards on the nine-month anniversary of the merger closing date.

Key Dates

Keywords

SpringWorks Therapeutics, SWTX, Merck KGaA, Merger, SEC Form 4, Beneficial Ownership, Stock Options, Restricted Stock Units, Performance Share Units, Cash Acquisition, Biotechnology, Pharmaceuticals, Corporate Action, Executive Compensation